Rapport de M. James Richardson [pour 1869]

Richardson, Joanne

doi:10.4095/126281

Cited by 22 publications

(30 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The CM-cellulose column was eluted with a flow velocity of 25 ml x cm-2 x h-', and the eluate was fractionated using a drop counter adjusted to give fractions of 1.0 ml. The eluate was continuously monitored for absorbance at the fixed wavelength of pure cytochrome c from many different species [25,26]. This was mainly due to contaminating material, which probably was not protein but was most likely glycogen and also soluble ion-exchange cellulose leaking out of the columns [48].…”

Section: Resultsmentioning

confidence: 99%

“…Fe(II1)-cytochrome c was obtained by treatment of the cytochrome c with potassium hexacyanoferrate(II1) and Fe(I1)-cytochrome by treatment with sodium dithionite. The purity of cytochrome c was checked by following the change in quotient A410 nm/A280 nm of oxidized cytochrome c, since the determination of this quotient instead of the commonly used A,,, red/A280 ox is practicable even with very low concentrations of cytochrome c. A quotient A410/A280 of up to about 4.7 has been reported for pure cytochrome c preparations of various species [25,26], but this value is known to vary somewhat because of differences in the content of aromatic amino acid residues in cytochrome c of different species, which affects the molar absorbance of cytochrome c at 280nm [27]. The concentration of purified cytochrome c was determined at room temperature in a solution of near-neutral pH (either in phosphate buffer pH 6.50 or pH 7.00, about 0.15 M in phosphate, or in 0.2 M ammonium hydrogencarbonate, pH 7.8) at the wavelength of 410nm, which is isosbestic for Fe(I1) and Fe(II1)-cytochrome c [25].…”

Section: Spectrophotometric Measurementsmentioning

confidence: 99%

See 1 more Smart Citation

Change of Cytochrome c Structure during Development of the Mouse

Hennig

1975

European Journal of Biochemistry

View full text Add to dashboard Cite

The structure of cytochrome c during mouse development is investigated. For this purpose the amino acid sequence of cytochrome c of the adult mouse had to be determined. The structure of cytochrome c of adult differentiated mouse cells differs in two amino acid residues from the known amino acid sequence of rabbit cytochrome c. No indication of different forms of cytochrome c in the adult differentiated cells was obtained. The structure of cytochrome c from 11.5‐day‐old mouse embryos is identical with that of adult mouse tissues. Since germ cells after meiotic division are the immediate precursors of a new individual, the structure of cytochrome c from sperm‐containing mice testes was investigated. By means of chromatography of the cytochrome c and of peptide maps and amino acid analyses of its tryptic peptides, it is shown that mouse testis contains two isocytochromes c in about equal amount. The structure of one of these two isocytochromes c is identical with the structure of the adult‐type cytochrome c of mouse. The testis‐specific cytochrome c, which is assumed to be located in the sperm cells, differs in 13 of its 104 amino acid residues from the adult‐type cytochrome c. From comparison of the primary and the spatial structures of the adult‐type and the sperm‐type isocytochromes c with the known structures of cytochrome c of more than 65 different species it is concluded that the duplication of the cytochrome c structural gene, causing the existence of the two ontogenetic‐specific isocytochromes c in mouse, has occurred early in the evolution of eucaryotes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Spectrophotometric Measurementsmentioning

confidence: 99%

Change of Cytochrome c Structure during Development of the Mouse

Hennig

1975

European Journal of Biochemistry

View full text Add to dashboard Cite

show abstract

“…The damage is often catalysed by impurities in the writing surface either directly or causally induced [12]. Just trace elements are involved in a variety of ways in decay processes of cellulose.…”

Section: Contaminations In Papermentioning

confidence: 99%

“…They seem to be the main cause of various damage mechanisms. Examples therefore include cellulose degradation processes by acidic components or oxidative degradation of cellulose, catalysed by traces of heavy metal [12].…”

Section: Mechanisms Of Pollutant Entry Into Papermentioning

confidence: 99%

See 1 more Smart Citation

Antiquarian Books as Source of Environment Historical Data

Schram¹,

Horst²,

Schneider³

et al. 2013

Cellulose - Medical, Pharmaceutical and Electronic Applications

View full text Add to dashboard Cite

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance

2023

View full text Add to dashboard Cite

ImportancePlatinum-based chemotherapy has been the standard of care for ovarian cancer for the past 3 decades. Although most patients respond to platinum-based treatment, emergence of platinum resistance in recurrent ovarian cancer is inevitable during the disease course. Outcomes for patients with platinum-resistant ovarian cancer are poor, and options remain limited, highlighting a substantial unmet need for new treatment options.ObservationsThis review summarizes the current and evolving treatment landscape for platinum-resistant ovarian cancer with a focus on the development of novel compounds. Biologic and targeted therapies such as bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors—originally approved in the platinum-resistant setting but since withdrawn—are now used in the up-front or platinum-sensitive setting, prolonging the duration of platinum sensitivity and delaying the use of nonplatinum options. The greater use of maintenance therapy and the emphasis on using platinum beyond first-line treatment has most likely been associated with a greater number of lines of platinum therapy before a patient is designated as having platinum-resistant ovarian cancer. In this contemporary setting, recent trials in platinum-resistant ovarian cancer have mostly had negative outcomes, with none having a clinically significant effect on progression-free or overall survival since the approval of bevacizumab in combination with chemotherapy. Nonetheless, a multitude of new therapies are under evaluation; preliminary results are encouraging. A focus on biomarker-directed treatment and patient selection may provide greater success in identifying novel therapies for treating platinum-resistant ovarian cancer.Conclusions and RelevanceAlthough many clinical trials in platinum-resistant ovarian cancer have had negative outcomes, these failures provide insights into how clinical trial design, biomarker-directed therapy, and patient selection could facilitate future successes in platinum-resistant ovarian cancer treatment.

show abstract

Rapport de M. James Richardson [pour 1869]

Cited by 22 publications

References 0 publications

Change of Cytochrome c Structure during Development of the Mouse

Change of Cytochrome c Structure during Development of the Mouse

Antiquarian Books as Source of Environment Historical Data

Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance

Contact Info

Product

Resources

About